Lung Cancer Trials Ask AI to find trials
Active Not RecruitingPhase 3NCT03815643
Official study title

Avelumab Program Rollover Study

Study summary

The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedAvelumab

The study team can explain what participation involves.

Who it may be forSolid Tumors

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 22, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 3

Interventional

Where is it offered?104 U.S. locations

Locations may change over time.

Who runs it?EMD Serono Research & Development Institute, Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 3
Sponsor
EMD Serono Research & Development Institute, Inc.
Interventions being studied
Drug: Avelumab
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Participants under enrollment and treatment in an avelumab clinical study under the sponsorship of EMD Serono Research \& Development Institute, Inc. / Merck KGaA, Darmstadt, Germany
  • Merck Serono Co., Ltd (Japan)
  • Participants currently enrolled in an avelumab parent study and are on active treatment with avelumab or in long-term survival follow-up after treatment
  • Participants on active treatment must agree to continue to use highly effective contraception (that is, methods with a failure rate of less than 1% per year) for both male and female participants if the risk of conception exists
  • Other protocol defined inclusion criteria could apply.
Reasons someone may not be able to joinExclusion criteria
  • Participants who are pregnant or breastfeeding
  • Participants still on active treatment: Known hypersensitivity to any of the study intervention ingredients
  • Participant has been enrolled in the comparator arm of avelumab parent study
  • Participant has been withdrawn from avelumab parent study for any reason
  • Any other reason that, in the opinion of the Investigator, precludes the participant from participating in the study
  • Other protocol defined

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • HonorHealth Research InstituteScottsdale, Arizona
  • Highlands Oncology GroupFayetteville, Arkansas
  • University of California Davis Health System - Comprehensive Cancer CenterSacramento, California
  • Providence Medical FoundationSanta Rosa, California
  • St Joseph Heritage HealthcareSanta Rosa, California
  • Norwalk Hospital - The Whittingham Cancer CenterNorwalk, Connecticut
  • Hematology - Oncology Associates of the Treasure Coast - Hematology-Oncology Associates of Treasure CoastPort Saint Lucie, Florida
  • Northwest Georgia Oncology CentersMarietta, Georgia
  • Maryland Oncology Hematology, P.A.Rockville, Maryland
  • Michigan State UniversityLansing, Michigan
  • Virginia Piper Cancer InstituteMinneapolis, Minnesota
  • Kansas City Research Institute, LLC - Phase I UnitKansas City, Missouri

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 22, 2026. Always confirm current availability with the study team.

View original record ↗